Literature DB >> 27703058

Distribution of ESBLs, AmpC β-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).

Shio-Shin Jean1,2, Po-Ren Hsueh3.   

Abstract

OBJECTIVES: To investigate the antimicrobial resistance and assess the molecular characteristics of β-lactamases (ESBLs, AmpC β-lactamases and carbapenemases) among Enterobacteriaceae isolates that caused intra-abdominal infections (IAIs) in patients hospitalized in the Asia-Pacific region during 2008-14.
METHODS: Multiplex PCR was used to detect the specific types of β-lactamase in 2893 isolates with MICs of ertapenem >0.5 mg/L. In-hospital acquisition times for most isolates were also delineated.
RESULTS: Among 2728 (94.3%) isolates proven with β-lactamase production, the rates of non-susceptibility to imipenem were low (average = 7.9%) among IAI Enterobacteriaceae isolates from all Asia-Pacific countries except Vietnam (17.7%) and the Philippines (10.2%). A stepwise and significant increase in annual rates of carbapenemase production among these isolates was noted. CTX-M-15 and CTX-M-14 were the dominant ESBL variants in most IAI Enterobacteriaceae species. The most abundant AmpC β-lactamase variants were blaCMY-2 among isolates of Escherichia coli and blaDHA-1 among isolates of Klebsiella pneumoniae. In addition, the IAI Enterobacteriaceae isolates harbouring a blaCMY-2 or blaDHA-1 allele were associated with high community-acquired rates (38.0% and 42.6%, respectively). AmpC ACT and MIR variants were mostly detected in Enterobacter species. The blaNDM-1,4,5,7-harbouring isolates of E. coli, K. pneumoniae and Enterobacter cloacae were most commonly identified among IAI isolates from Vietnam and the Philippines. Also of note, blaOXA-48-harbouring IAI Enterobacteriaceae isolates were detected exclusively in Vietnam.
CONCLUSIONS: The high resistance burden in Vietnam and the Philippines warrants aggressive control policies to combat the worsening trend in antimicrobial resistance among Enterobacteriaceae species causing IAIs.
© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27703058     DOI: 10.1093/jac/dkw398

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  27 in total

1.  Emerging antimicrobial resistance among Escherichia coli strains in bloodstream infections in Toronto, 2006-2016: a retrospective cohort study.

Authors:  Sophie Mineau; Robert Kozak; Melissa Kissoon; Aimee Paterson; Anthony Oppedisano; Firas Douri; Kate Gogan; Barbara M Willey; Allison McGeer; Susan M Poutanen
Journal:  CMAJ Open       Date:  2018-12-03

2.  Impact of Inducible blaDHA-1 on Susceptibility of Klebsiella pneumoniae Clinical Isolates to LYS228 and Identification of Chromosomal mpl and ampD Mutations Mediating Upregulation of Plasmid-Borne blaDHA-1 Expression.

Authors:  Adriana K Jones; Srijan Ranjitkar; Sara Lopez; Cindy Li; Johanne Blais; Folkert Reck; Charles R Dean
Journal:  Antimicrob Agents Chemother       Date:  2018-09-24       Impact factor: 5.191

3.  Prevalence and risk factors for intestinal carriage of CTX-M-type ESBLs in Enterobacteriaceae from a Thai community.

Authors:  P R Niumsup; U Tansawai; A Na-Udom; D Jantapalaboon; K Assawatheptawee; A Kiddee; T Romgaew; S Lamlertthon; T R Walsh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-16       Impact factor: 3.267

4.  Characterization of β-Lactamase Content of Ceftazidime-Resistant Pathogens Recovered during the Pathogen-Directed Phase 3 REPRISE Trial for Ceftazidime-Avibactam: Correlation of Efficacy against β-Lactamase Producers.

Authors:  Rodrigo E Mendes; Mariana Castanheira; Leah N Woosley; Gregory G Stone; Patricia A Bradford; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2019-05-24       Impact factor: 5.191

5.  Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017.

Authors:  Krystyna M Kazmierczak; James A Karlowsky; Boudewijn L M de Jonge; Gregory G Stone; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

6.  A rapid, antibiotic susceptibility test for multidrug-resistant, Gram-negative bacterial uropathogens using the biochemical assay, DETECT.

Authors:  Nicole Jackson; Clarissa A Borges; Nicole J Tarlton; Angel Resendez; Aubrianne K Milton; Tara R de Boer; Cheyenne R Butcher; Niren Murthy; Lee W Riley
Journal:  J Microbiol Methods       Date:  2021-02-04       Impact factor: 2.363

7.  Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital.

Authors:  Qinjie Liu; Jianan Ren; Xiuwen Wu; Gefei Wang; Zhiwei Wang; Jie Wu; Jinjian Huang; Tianyu Lu; Jieshou Li
Journal:  BMC Infect Dis       Date:  2017-09-21       Impact factor: 3.090

8.  Gut microbiome signatures of nursing home residents carrying Enterobacteria producing extended-spectrum β-lactamases.

Authors:  Quentin Le Bastard; Guillaume Chapelet; Gabriel Birgand; Benjamin M Hillmann; François Javaudin; Niki Hayatgheib; Céline Bourigault; Pascale Bemer; Laure De Decker; Eric Batard; Didier Lepelletier; Emmanuel Montassier
Journal:  Antimicrob Resist Infect Control       Date:  2020-07-14       Impact factor: 4.887

9.  A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China.

Authors:  Yijian Chen; Demei Zhu; Yingyuan Zhang; Yongjie Zhao; Gang Chen; Ping Li; Lihong Xu; Ping Yan; M Anne Hickman; Xiajun Xu; Margaret Tawadrous; Michele Wible
Journal:  Ther Clin Risk Manag       Date:  2018-11-30       Impact factor: 2.423

10.  In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Shio-Shin Jean; Min-Chi Lu; Zhi-Yuan Shi; Shu-Hui Tseng; Ting-Shu Wu; Po-Liang Lu; Pei-Lan Shao; Wen-Chien Ko; Fu-Der Wang; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2018-10-26       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.